探讨儿童急性淋巴细胞白血病(acute lymphoblastic leukemia，ALL)CD₃₄⁺表达的临床意义。

采集54例ALL患儿的骨髓标本，分别进行细胞形态学及细胞化学染色，确定其FAB类型，运用一组相关的单克隆抗体，采用流式细胞仪及直接免疫荧光标记技术进行免疫学检查，采用吉姆萨G显带技术进行核型分析。

儿童ALL CD₃₄⁺表达59. 26%(32/54)。CD₃₄⁺表达与ALL免疫分型无关，临床上与初诊时的WBC，Hb，PLT无关，而与肝、脾或淋巴结肿大等髓外浸润有关。细胞遗传学异常患儿CD₃₄⁺表达发生率较高。但CD₃₄⁺与CD₃₄^- ALL患儿CR率差异无统计学意义(χ²= 0. 982,P= 0. 396)。

采用强烈的化疗方案治疗ALL，CD₃₄⁺表达对化疗的临床疗效无明显影响。

To explore CD₃₄⁺ expression in childhood acute lymphoblastic leukemia(ALL)and its clinical implication.

Immunophenotype analysis was performed on bone marrow aspirates from 54 patients diagnosed as ALL by the French, American and British(FAB)criteria using a comprehensive panel of monoclonal antibodies to lymphoid and myeloid associated antigens.

Expression of CD₃₄ antigen was found in 32 out of 54 ALL children(59. 26%). And it was close relation with metastasis outside bone marrow, such as hepatosplenomegaly and swelling of lymph nodes(χ²= 6. 102,P= 0. 021), but not with white blood cell(WBC)count, hemoglobin level and platelet count(P> 0. 05). Though most ALL patients with CD₃₄⁺ expression had cytogenetic abnormity, complete remission(CR)rate was no difference between ALL patients with CD34⁺ expression and those without.

CD34 antigen expression was detected in a lot of ALL patients, but it was not associated with progression of childhood ALL as a result of intensive chemotherapy carried out.